Recorded live from the Ai4 conference floor in Las Vegas, Sam sits down with Dilo Wijesuriya, President & COO of ARC Document Solutions, to talk about the unglamorous but essential layer of enterprise AI: getting decades of paper archives into a format models can actually learn from.

What's Covered:

The Technology — ARC holds patents for OCR on wide-format documents (architectural drawings, engineering blueprints) that standard scanning tools can't accurately process, backed by a 200-person engineering team in India.

Security & Compliance — SOC 2, SOC 3, ISO 27001, and HIPAA compliant, running on AWS — built for regulated industries like healthcare and financial services.

Will Paper Disappear? Dilo's view: not for a long time. Most organizations' most critical institutional knowledge still exists only on paper, meaning today's LLMs simply can't learn from it yet.

The Book Destruction Debate — A direct response to recent controversy over companies destroying physical books after digitizing them, and why ARC's non-destructive robotic scanning preserves originals for high-value collections at universities, libraries, and museums.

Looking Ahead — Why Dilo believes the next competitive advantage for most enterprises isn't a better model — it's finally accessing the data already sitting in their own archives.

Key Quote: "The challenge isn't finding more data. It's making existing information accessible."

Connect with Dilo and ARC:

Dilo Wijesuriya: https://www.linkedin.com/in/dilo-wijesuriya/

ARC Document Solution: https://www.e-arc.com/

Subscribe: Spotify | Apple Podcasts | Amazon Music | iHeart Radio | YouTube

#Ai4Conference #DocumentDigitization #AIReadyData #EnterpriseAI #OCR #AsembleAI

This episode was recorded live from the Ai4 conference podcast pavilion, where host Mac Goswami sat down with Kathryn Harrison, Global VP of Strategy in AI Commercialization at Concentrix — and an exited founder who built and sold the B2B SaaS platform MakePay, founded Deep Trust Alliance, and previously helped lead IBM Blockchain — about what it actually takes to turn AI into measurable value across a global enterprise.

What's Covered:

Humans Plus AI, at Global Scale — Concentrix runs customer and technical support across 75 countries and 150 languages. Kathryn makes the case that the future workforce isn't AI replacing people — it's humans plus AI and automation — and what that looks like across 400,000 employees with segmented AI access.

Three Rules for Commercializing AI — Kathryn's framework for doing it at scale: start with outcome-based use cases, redesign the work instead of bolting AI on, and build in guardrails, integration, compliance, observability, and humans-in-the-loop. Plus why she frames "tokenomics" as capital allocation.

The Agentic Operating System — How Concentrix uses agentic workflows to recruit and onboard 50,000 hires a year, with a 21-day implementation goal — a real production system, not a demo.

From Pilots to ROI — Why most AI stalls before it delivers, how to actually measure return, and where enterprise AI spend most often goes wrong.

The Deepfake Threat — Drawing on her work founding Deep Trust Alliance, Kathryn on the rise of deepfake-driven fraud, how it differs from traditional cybersecurity, and the broader societal risks.

The Coming Shakeout — Orchestration across messy client tech stacks, consolidation among AI startups, and where Kathryn sees AI and automation heading next.

Connect with Kathryn:
LinkedIn: https://www.linkedin.com/in/kathrynannharrison/
Concentrix: https://www.concentrix.com/
Deep Trust Alliance: https://www.deeptrustalliance.org/

Follow and subscribe to AsembleAI: Spotify | Apple Podcasts | Amazon Music | iHeart Radio | YouTube | Substack

#Ai4Conference #AICommercialization #Deepfakes #AgenticAI #Concentrix #AsembleAI

This episode was recorded live from the Ai4 conference podcast pavilion, Sam sat down with Alex Zhavoronkov, Founder & CEO of Insilico Medicine, about what it actually takes to turn AI-generated molecules into approved drugs.

What's Covered:

From Laughed-Out-of-the-Room to 33 Candidates — Alex pitched generative AI for drug design in 2015 and got dismissed. Today: 33 developmental candidates in six years, zero failed toxicity studies, and deals with Eli Lilly, Takeda, Servier, and SK Bio at a pace of nearly one per month.

The Real Bottleneck — "It's not about a story. Many people in our field love to tell a story, but they don't have a single drug in the clinic discovered by AI." Alex's direct take on separating hype from results in AI drug discovery.

A Lucky Breakthrough — The story of how Insilico stumbled onto a novel, non-opioid pain mechanism that outperformed morphine in animal testing — now targeting a $70 billion market.

Why Abu Dhabi — Not for speed, but for geopolitical neutrality. Alex explains why Insilico built a 60-person AI lab in the UAE, and how two drugs now trace their origin to the Middle East for the first time in modern history.

Quantum-Generated Drugs — A December 2025 Nature Biotechnology cover story: a molecule generated on a real IBM quantum computer, validated experimentally, with the University of Toronto.

Pharmaceutical Superintelligence vs. AGI — Where Alex thinks AI drug discovery already stands, and why he draws a hard line between a useful scientific partner and the "conscious AI God" version of AGI.

Key Quote: "In terms of pharmaceutical superintelligence, we're very close to being there. In terms of AGI - the future AI God - we're still not there, and we might never get there."

Connect with Alex:

LinkedIn: https://www.linkedin.com/in/zhavoronkov/

Insilico Medicine Website: https://insilico.com/

Alex's published manuscript about longevity medicine in the Nature journal: https://www.nature.com/articles/s43587-020-00020-4

Follow and subscribe to AsembleAI: Spotify | Apple Podcasts | Amazon Music | iHeart Radio | YouTube | Substack

#Ai4Conference #InsilicoMedicine #DrugDiscoveryAI #Longevity #AsembleAI